Stock Markets June 16, 2026 02:00 PM

Cyber extortion group claims theft of more than 1TB from Novo Nordisk, says $25 million demand was refused

FulcrumSec alleges prolonged access to internal systems including source code, clinical trial files and production software; Novo Nordisk had earlier disclosed limited unauthorized IT access

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
NVO

A cyber extortion collective identifying itself as FulcrumSec posted claims that it removed roughly 1.3 terabytes of data from Novo Nordisk after spending more than two months inside the company's networks. The group says it sought a $25 million payment that the company did not meet and is now exploring private sales of parts of the material while withholding certain personal and operational files as a harm-reduction measure. Novo Nordisk confirmed a cybersecurity incident earlier this month involving unauthorized access to a limited set of internal IT systems and certain personal data; neither the company nor FulcrumSec immediately responded to requests for comment on the extortion group's public assertions.

Cyber extortion group claims theft of more than 1TB from Novo Nordisk, says $25 million demand was refused
NVO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FulcrumSec claims to have removed approximately 1.3 terabytes of data from Novo Nordisk after spending over two months inside the company's networks.
  • The extortion group alleges it sought $25 million in payment; when the company did not pay, FulcrumSec said it is exploring private sales of some of the material but will withhold certain personal and operational files.
  • Sectors directly affected include pharmaceuticals and healthcare, while broader implications touch cybersecurity services and market sentiment for the company and related health-tech providers.

FulcrumSec, a cyber extortion collective that the group says emerged in October 2025, posted a lengthy message on its website on Tuesday claiming it exfiltrated more than a terabyte of material from global pharmaceutical company Novo Nordisk after spending in excess of two months inside the firm's networks.

According to the posting, the stolen data set includes company source code, proprietary information on both released and unreleased medicines, clinical trial data, personal details for employees, physicians and roughly 11,500 pseudonymised clinical trial participants, information tied to production facilities and internal artificial intelligence model material.

FulcrumSec said it opened a channel with Novo Nordisk seeking payment of $25 million, which the group alleges the company did not provide. After that refusal, the group said it is "exploring private sales" of certain drug-related records and other internal files. The group stated it would not distribute some categories of data, including information on thousands of company employees and physicians and the approximately 11,500 pseudonymised clinical trial subjects. It also said it would withhold material related to operational technology and software that interacts with sensors and machinery at production sites, describing that withholding as part of a "harm-reduction strategy."

On June 11 the Danish company publicly disclosed a cybersecurity incident, saying that unauthorized access had been detected involving a limited number of internal IT systems and that certain personal data had been accessed. Novo Nordisk did not immediately reply to a request for comment about the specific claims made by FulcrumSec. The extortion group also did not immediately answer requests for comment on the assertions posted to its website. Reuters could not immediately verify the authenticity of the data published by the group.

Thomas Willkan, head of research at cybersecurity firm Lab-1 who has been tracking FulcrumSec closely, said the group is "usually quite legit in terms of both their capabilities and also their claims." The post and subsequent reporting identify a file list of more than 700,000 items, representing roughly 1.3 terabytes of data, that FulcrumSec presented in correspondence it says began on June 1.

Independent cybersecurity-focused outlets reported related developments. A blog covering data breaches and extortion reported on June 15 that FulcrumSec told the blog it first gained access to Novo Nordisk's network in March and shared alleged correspondence starting June 1 listing the files. Separately, a malware research repository reported that an unnamed hacker had compromised Novo Nordisk, though FulcrumSec said its claimed attack is separate from that reporting.

FulcrumSec's public statement asserts a wide range of sensitive categories were taken, spanning software assets, clinical materials and personal data. The group also set out limits on what it will publicly release, indicating a selective approach to distribution. Novo Nordisk is widely known for treatments for obesity and diabetes, including Wegovy and Ozempic, and the company has acknowledged the cybersecurity incident while the claims by the extortion group remain unverified by independent parties.


Summary of known facts:

  • FulcrumSec claims it spent more than two months inside Novo Nordisk networks and stole roughly 1.3 terabytes of data.
  • The group says it sought $25 million from Novo Nordisk and, after the company did not pay, is exploring private sales of some files while withholding certain personal and operational data.
  • Nov o Nordisk disclosed unauthorized access to a limited number of internal IT systems on June 11; neither the company nor FulcrumSec immediately responded to requests for comment and independent verification of the posted data has not been established.

Risks

  • Unverified claims mean uncertainty over the scope and authenticity of the stolen material, which affects assessments of potential operational, legal or reputational impacts on the pharmaceutical sector.
  • If sensitive clinical or proprietary drug-development data were exposed, there could be regulatory, patient privacy and competitive risks for affected parties in healthcare and pharma.
  • Potential market and investor reaction to ongoing uncertainty around the breach and extortion could influence shares and related financial instruments in the pharmaceutical sector and increase demand for cybersecurity services.

More from Stock Markets

Insider Purchase Sparks Rally in Pelthos Therapeutics Shares Jun 16, 2026 TD Cowen Names Walmart Its Top Idea for 2026, Citing Strengthening Price Power and Digital Profit Mix Jun 16, 2026 Goldman Tops $1 Trillion in H1 M&A, Citing SpaceX IPO and AI-Led Momentum Jun 16, 2026 Tropical Disturbance Near Texas Coast Threatens Heavy Rain, Flooding and Energy Disruptions Jun 16, 2026 Options Activity in Northern Oil & Gas Surges to 3,687 Contracts Jun 16, 2026